Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche MS drug Ocrevus...

    Roche MS drug Ocrevus approved by FDA after three-month delay

    Written by supriya kashyap kashyap Published On 2017-03-29T11:57:26+05:30  |  Updated On 29 March 2017 11:57 AM IST
    Roche MS drug Ocrevus approved by FDA after three-month delay

    The U.S. Food and Drug Administration (FDA) approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay by regulators over manufacturing issues.


    The injectable drug, known chemically as ocrelizumab becomes the first U.S. approved medicine for primary progressive form of the neurological disease (PPMS).


    The drug's entry into the U.S. market was delayed by three months when the FDA in late December pushed back its deadline for an approval a decision, saying the commercial manufacturing process for Ocrevus was not yet ready.


    Ocrevus, an immuno suppressive drug that reduces the immune system's assault on the body's own neurons, could become a mainstay treatment for MS and help offset falling revenue from Roche's top-selling cancer drugs Rituxan, Avastin and Herceptin that will soon face competition from cheaper biosimilar versions.


    Analysts forecast annual sales exceeding $3 billion by 2021, according to Reuters data.


    Roche rival Novartis AG is also developing its own MS treatment, BAF312 for secondary progressive multiple sclerosis, and expects regulatory approval in the first half of 2017 depending on the outcome of talks with regulators.


    Other companies are also seeking new drug alternatives for different forms of MS, including GeNeuro SA.


    Roche said in the PPMS study, patients who got Ocrevus were 47 percent more likely than those who received placebo to have no evidence of disease progression.

    MS drugmultiple sclerosisMultiple Sclerosis Drugneurological diseaseNovartisOcrevusRocheUS Food and Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok